Quent Capital LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Quent Capital LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 411 shares of the biopharmaceutical company’s stock after purchasing an additional 21 shares during the quarter. Quent Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $432,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in REGN. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. MCF Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $37,000. Finally, BOK Financial Private Wealth Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $37,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.5 %

Shares of Regeneron Pharmaceuticals stock traded down $5.09 during trading on Tuesday, reaching $1,066.19. The company’s stock had a trading volume of 421,180 shares, compared to its average volume of 471,332. The company has a quick ratio of 4.51, a current ratio of 5.96 and a debt-to-equity ratio of 0.10. The company has a market cap of $117.48 billion, a price-to-earnings ratio of 31.89, a P/E/G ratio of 2.32 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $765.28 and a 1-year high of $1,115.00. The company has a 50-day simple moving average of $1,045.15 and a two-hundred day simple moving average of $984.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the firm earned $8.79 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.45 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock valued at $64,546,123 in the last quarter. 7.48% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Bank of America increased their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday. UBS Group raised their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,097.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.